6.21
price up icon0.16%   0.010
pre-market  Pre-market:  6.21  
loading
Decoy Therapeutics Inc stock is traded at $6.21, with a volume of 5,590. It is up +0.16% in the last 24 hours and down -18.50% over the past month. Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
See More
Previous Close:
$6.20
Open:
$6.05
24h Volume:
5,590
Relative Volume:
0.03
Market Cap:
$3.30M
Revenue:
-
Net Income/Loss:
$-12.52M
P/E Ratio:
-0.0514
EPS:
-120.8826
Net Cash Flow:
$-4.83M
1W Performance:
+10.30%
1M Performance:
-18.50%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$6.03
$6.40
1-Week Range:
Value
$5.63
$6.70
52-Week Range:
Value
$5.40
$16.92

Decoy Therapeutics Inc Stock (DCOY) Company Profile

Name
Name
Decoy Therapeutics Inc
Name
Phone
346-772-0346
Name
Address
2450 HOLCOMBE BLVD, HOUSTON
Name
Employee
11
Name
Twitter
Name
Next Earnings Date
2026-04-03
Name
Latest SEC Filings
Name
DCOY's Discussions on Twitter

Compare DCOY vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
DCOY icon
DCOY
Decoy Therapeutics Inc
6.21 3.30M 0 -12.52M -4.83M -120.88
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
441.70 112.35B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
753.93 79.71B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
840.87 52.29B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
333.39 44.48B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
319.94 35.51B 5.36B 287.73M 924.18M 2.5229

Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-23-26 Initiated Ladenburg Thalmann Buy
Apr-27-20 Initiated Ladenburg Thalmann Buy

Decoy Therapeutics Inc Stock (DCOY) Latest News

pulisher
Apr 10, 2026

DCOY Price Today: Decoy Therapeutics Inc. Stock Price, Quote & Chart - MEXC

Apr 10, 2026
pulisher
Apr 10, 2026

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline - BioSpace

Apr 10, 2026
pulisher
Apr 09, 2026

Transcript : Decoy Therapeutics Inc.Special Call - marketscreener.com

Apr 09, 2026
pulisher
Apr 09, 2026

Decoy Therapeutics outlines antiviral pipeline milestones By Investing.com - Investing.com South Africa

Apr 09, 2026
pulisher
Apr 09, 2026

Decoy Therapeutics outlines antiviral pipeline milestones - Investing.com

Apr 09, 2026
pulisher
Apr 09, 2026

Decoy Therapeutics Launches Multi-Virus Antiviral Platform - Intellectia AI

Apr 09, 2026
pulisher
Apr 09, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm

Apr 09, 2026
pulisher
Apr 07, 2026

DCOY Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 07, 2026
pulisher
Apr 06, 2026

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 - Finviz

Apr 06, 2026
pulisher
Apr 03, 2026

Decoy Therapeutics Inc (STU:FP11) Stock Earnings Transcripts - GuruFocus

Apr 03, 2026
pulisher
Apr 03, 2026

Decoy Therapeutics Inc (STU:FP11) Stock Price & 30 Year Financial Data - GuruFocus

Apr 03, 2026
pulisher
Apr 03, 2026

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Bitget

Apr 03, 2026
pulisher
Apr 02, 2026

Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Apr 02, 2026
pulisher
Apr 02, 2026

Decoy Therapeutics regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Australia

Apr 02, 2026
pulisher
Apr 02, 2026

Decoy Therapeutics regains Nasdaq minimum bid price compliance - Investing.com

Apr 02, 2026
pulisher
Apr 02, 2026

Decoy Therapeutics Regains Nasdaq Compliance After Reverse Split - TipRanks

Apr 02, 2026
pulisher
Apr 02, 2026

Decoy Therapeutics regains compliance with Nasdaq minimum bid price requirement - marketscreener.com

Apr 02, 2026
pulisher
Apr 02, 2026

Decoy Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement - TradingView

Apr 02, 2026
pulisher
Apr 02, 2026

Decoy Therapeutics regains Nasdaq minimum bid compliance after reverse split - TradingView — Track All Markets

Apr 02, 2026
pulisher
Apr 02, 2026

Decoy Therapeutics (DCOY) restores Nasdaq bid-price compliance after reverse split - Stock Titan

Apr 02, 2026
pulisher
Mar 31, 2026

DCOY: 2025 net loss rose to $12.5M, with cash runway into late 2026 but going concern risk persists - TradingView

Mar 31, 2026
pulisher
Mar 31, 2026

Decoy Therapeutics 10-K: Net loss $12.52M, EPS $(129.10) - TradingView — Track All Markets

Mar 31, 2026
pulisher
Mar 31, 2026

Decoy Therapeutics (NASDAQ: DCOY) details AI antiviral platform, merger and reverse stock splits - Stock Titan

Mar 31, 2026
pulisher
Mar 31, 2026

Decoy Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 31, 2026
pulisher
Mar 30, 2026

Decoy Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 30, 2026
pulisher
Mar 26, 2026

Total liabilities & shareholders' equities of Decoy Therapeutics Inc. – FWB:FP11 - TradingView

Mar 26, 2026
pulisher
Mar 23, 2026

Nabriva Therapeutics (NASDAQ:NBRV) and Decoy Therapeutics (NASDAQ:DCOY) Head to Head Survey - Defense World

Mar 23, 2026
pulisher
Mar 23, 2026

If You Invested $1,000 in Salarius Pharmaceuticals Inc (SLRX) - Stock Titan

Mar 23, 2026
pulisher
Mar 20, 2026

Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | | US79400X6022 - marketscreener.com

Mar 20, 2026
pulisher
Mar 20, 2026

Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FP11 | US79400X6022 - marketscreener.com

Mar 20, 2026
pulisher
Mar 19, 2026

Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | DCOY | US79400X6022 - marketscreener.com

Mar 19, 2026
pulisher
Mar 15, 2026

Decoy Therapeutics partners with Quantori on AI peptide platform By Investing.com - Investing.com Nigeria

Mar 15, 2026
pulisher
Mar 12, 2026

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform - Lelezard

Mar 12, 2026
pulisher
Mar 11, 2026

Decoy Therapeutics Inc. Earnings and Revenue – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Debt to equity ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

EBIT per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Price to cash flow ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Free cash flow per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Net margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Revenue per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Operating margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Net current asset value per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Enterprise value to EBITDA ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Non-controlling/minority interest of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Price to book ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Total operating expenses of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

CapEx per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Equity in earnings of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

EBIT of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Total debt per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Debt to assets ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView

Mar 11, 2026

Decoy Therapeutics Inc Stock (DCOY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$54.26
price up icon 2.69%
$48.70
price down icon 0.25%
$99.47
price up icon 1.08%
$152.54
price up icon 3.76%
$146.74
price down icon 4.34%
ONC ONC
$319.94
price up icon 3.21%
Cap:     |  Volume (24h):